The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases
Open accessAbstract
BACKGROUND.: There are limited effective treatment options available and a poor 5‐year survival for patients with inoperable neuroendocrine liver metastases (NETLMs). In this study, the authors prospectively assessed the safety and efficacy of treatment with yttrium 90 (90 Y) radioactive microspheres for patients with unresectable NETLMs. METHODS.: Radioactive 90 Y resin microspheres (selective internal radiation [SIR‐Spheres]) were administered through a temporarily placed percutaneous hepatic artery catheter concomitantly with a 7‐day systemic infusion of 5‐fluorouracil to patients with progressive, unresectable NETLMs. Patients were monitored prospectively, and the response to treatment was measured by using cancer markers and tumor size on computed tomography imaging studies. RESULTS.: Thirty‐four patients (22 men) with a mean age 61 years (range, 32‐79 years) who had unresectable NETLMs were treated between December 2003 and December 2005. The mean (±standard error) follow‐up was 35.2 ± 3.2 months. The site of the primary neuroendocrine tumor was the bronchus in 1 patient, the medullary thyroid in 2 patients, gastrointestinal in 15 patients, the pancreas in 8 patients, and of unknown origin in 8 patients. The tumors were classified as vipoma (1 tumor), somatostatinoma (1 tumor), glucagonoma (2 tumors), large cell (3 tumors), carcinoid (25 tumors), and of unknown origin (2 tumors). Complications after 90 Y radioembolization included abdominal pain, which was mild to severe; nausea and fever; and lethargy that lasted from 1 week to 1 month. Two patients developed biopsy‐proven radiation gastritis, 1 patient developed a duodenal ulcer, and there was 1 early death from liver dysfunction and pneumonia. Subjective changes from recorded baseline hormone symptoms were reported every 3 months. Symptomatic responses were observed in 18 of 33 patients (55%) at 3 months and in 16 of 32 patients (50%) at 6 months. Radiologic liver responses were observed in 50% of patients and included 6 (18%) complete responses and 11 (32%) partial responses, and the mean overall survival was 29.4 ± 3.4 months). In patients who had evaluable chromogranin A (CgA) marker levels, there was a fall in CgA marker levels after 90 Y radioembolization in 19 patients (26%) at 1 month, in 19 patients (41%) at 3 months, in 15 patients (43%) at 6 months, in 11 patients (42%) at 12 months, in 8 patients (38%) at 24 months, and in 3 patients (46%) at 30 months. CONCLUSIONS.: In this open study of 34 patients, the results demonstrated that radioembolization with 90 Y resin microspheres can achieve relatively long‐term responses in some patients with nonresectable NETLMs. Cancer 2008. © 2008 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Accelerated image reconstruction using ordered subsets of projection data
Hudson, H. M., & Larkin, R. S. (1994) · IEEE Transactions on Medical Imaging · doi:10.1109/42.363108 · Cited by 3,711
Hepatic neuroendocrine metastases: does intervention alter outcomes?1
Chamberlain, R. S., Canes, D., Brown, K. T., Saltz, L., Jarnagin, W., Fong, Y., & Blumgart, L. H. (2000) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(00)00222-2 · Cited by 622
Öberg, K., Kvols, L., Caplin, M., Delle Fave, G., de Herder, W., Rindi, G., Ruszniewski, P., Woltering, E. A., & Wiedenmann, B. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh216 · Cited by 577
Gray, B., Van Hazel, G., Hope, M., Burton, M., Moroz, P., Anderson, J., & Gebski, V. (2001) · Annals of Oncology · doi:10.1023/a:1013569329846 · Cited by 526
Gupta, S., Johnson, M. M., Murthy, R., Ahrar, K., Wallace, M. J., Madoff, D. C., McRae, S. E., Hicks, M. E., Rao, S., Vauthey, J., et al. (2005) · Cancer · doi:10.1002/cncr.21389 · Cited by 433
Kennedy, A. S., Coldwell, D., Nutting, C., Murthy, R., Wertman, D. E., Loehr, S. P., Overton, C., Meranze, S., Niedzwiecki, J., & Sailer, S. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.12.051 · Cited by 375
Neuroendocrine Hepatic Metastases: Does Aggressive Management Improve Survival?
Touzios, J. G., Kiely, J. M., Pitt, S. C., Rilling, W. S., Quebbeman, E. J., Wilson, S. D., & Pitt, H. A. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000161981.58631.ab · Cited by 362
Sun, W., Lipsitz, S., Catalano, P., Mailliard, J. A., & Haller, D. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.616 · Cited by 357
The Management of Patients with Advanced Carcinoid Tumors and Islet Cell Carcinomas
Moertel, C. G., Johnson, C. M., McKusick, M. A., Martin, J. K., Nagorney, D. M., Kvols, L. K., Rubin, J., & Kunselman, S. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-4-199402150-00008 · Cited by 292
Bolch, W. E., Bouchet, L. G., Js, R., Wessels, B. W., Ja, S., Howell, R. W., Ak, E., Aydogan, B., Costes, S. V., Ee, W., et al. (1999) · PubMed · Cited by 237
Osborne, D. A., Zervos, E. E., Strosberg, J., Boe, B. A., Malafa, M., Rosemurgy, A. S., Yeatman, T. J., Carey, L., Duhaine, L., & Kvols, L. K. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.03.071 · Cited by 220
[New guidelines to evaluate the response to treatment in solid tumors].
Duffaud, F., & Therasse, P. (2000) · PubMed · Cited by 174
Transcatheter chemoembolization of progressive carcinoid liver metastasis.
Therasse, E., Breittmayer, F., Roche, A., De Baere, T., Indushekar, S., Ducreux, M., Lasser, P., Elias, D., & Rougier, P. (1993) · Radiology · doi:10.1148/radiology.189.2.7692465 · Cited by 172
Gastrointestinal neuroendocrine tumors.
Delcore, R., & Friesen, S. R. (1994) · PubMed · Cited by 160
Radiofrequency Tissue Ablation Using Cooled Tip for Liver Metastases of Endocrine Tumors
Hellman, P., Ladjevardi, S., Skogseid, B., Åkerström, G., & Elvin, A. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6663-3 · Cited by 159
Ho, A. S., Picus, J., Darcy, M. D., Tan, B., Gould, J. E., Pilgram, T. K., & Brown, D. B. (2007) · American Journal of Roentgenology · doi:10.2214/ajr.06.0933 · Cited by 158
Liver transplantation for neuroendocrine tumors
Florman, S. S., Toure, B., Kim, L., Gondolesi, G. E., Roayaie, S., Nancy, K., Fishbein, T., Emre, S., Miller, C. C., & Schwartz, M. E. (2004) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2003.11.010 · Cited by 134
Lim, L., Gibbs, P., Yip, D., Shapiro, J., Dowling, R., Smith, D., Little, A. F., Bailey, W. T., & Liechtenstein, M. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-132 · Cited by 123
Hepatic Arterial Chemoembolization in the Management of Advanced Digestive Endocrine Tumors
Ruszniewski, P. B., & Malka, D. (2000) · Digestion · doi:10.1159/000051860 · Cited by 119
Chemotherapy in the Treatment of Neuroendocrine Malignant Tumors
Rougier, P. R., & Mitry, E. (2000) · Digestion · doi:10.1159/000051859 · Cited by 111
Rivera, E., & Ajani, J. A. (1998) · American Journal of Clinical Oncology · doi:10.1097/00000421-199802000-00008 · Cited by 92
Hajarizadeh, H., Ivancev, K., Mueller, C. R., Fletcher, W. S., & Woltering, E. A. (1992) · The American Journal of Surgery · doi:10.1016/0002-9610(92)90392-5 · Cited by 85
Murthy, R., Kamat, P. P., NUÑEZ, R. F., Madoff, D. C., Gupta, S. K., Salem, R., & Yao, J. C. (2008) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2007.09.006 · Cited by 69
Dhabuwala, A., Lamerton, P., & Stubbs, R. S. (2005) · BMC Nuclear Medicine · doi:10.1186/1471-2385-5-7 · Cited by 62
p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan
Nose, H., Imazeki, F., Ohto, M., & Omata, M. (1993) · Cancer · doi:10.1002/1097-0142(19930715)72:2
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Pavel, M., Baudin, E., Couvelard, A., Krenning, E., Öberg, K., Steinmüller, T., Anlauf, M., Wiedenmann, B., & Salazar, R. (2012) · Neuroendocrinology · doi:10.1159/000335597 · Cited by 873
Zaknun, J. J., Bodei, L., Mueller-Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O’Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 818
Jensen, R. T., Cadiot, G., Brandi, M. L., de Herder, W. W., Kaltsas, G., Komminoth, P., Scoazec, J.-Y., Salazar, R., Sauvanet, A., & Kianmanesh, R. (2012) · Neuroendocrinology · doi:10.1159/000335591 · Cited by 622
Metadata
- Authors
- King, J., Quinn, R., Glenn, D. M., Janssen, J., Tong, D., Liaw, W., & Morris, D. L.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-08-20
- Volume
- 113
- Issue
- 5
- Pages
- 921-929
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2004535742
- Cited by
- 284
- References
- 26
- FWCI
- 14.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.